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Hepatocellular carcinoma (HCC) is the fifth most common cancer
worldwide and is frequently associated with cirrhosis, chronic hepa-
titis B (HBV) and C (HCV) virus infection. The objective of our study
was to identify altered protein expression or glycosylation for use as
biomarkers in HCC. Quantitation of proteins in complex biological
samples using mass spectrometry has become feasible in recent years
using methods that rely on incorporation of stable isotopes into
peptides. Our approach was to use multiple technologies including the
multiplexed isotope labeling for relative quantitation of HCC asso-
ciated proteins using iTRAQ method and 18O based quantitation and
identification of tumor specific glycosylated proteins for the discovery
phase and Western blotting and immunohistochemical labeling of
HCC tissues for the validation phase. Two dimensional LC-MS/MS
analysis and glycoprotein enrichment strategy generated more than
50,000 MS/MS spectra from which we were able to identify and
quantitate more than 1,000 liver proteins in hepatocelluar carcinoma.
Over 200 proteins were found to be upregulated in HCC, which
included both previously described markers as well as novel ones.
Novel overexpressed proteins in HCC included fibroleukin, myeloid-
associated differentiation marker, prothymosin alpha, high mobility
group AT-hook 1 isoform a and leucine rich repeat containing 59.
Over 100 proteins were found to be downregulated in HCC relative to
adjacent normal tissues which included urea cycle enzymes, class I
and class II alcohol dehydrogenases, fatty acid binding protein 1 and
prostatic binding proteins. Western blotting confirmed the results of
both upregulated and downregulated proteins. Using immunohisto-
chemical labeling, we were able to validate overexpression of
fibroleukin, myeloid-associated differentiation marker and fetuin in
HCC and downregulation of urea cycle enzymes, fatty acid binding
protein and prostatic binding proteins in HCC using tissue micro-
arrays (n = 60). Lectin affinity enrichment was found to be
advantageous to quantitate several interesting proteins, which were
not detected in the whole proteome screening approach. Using lectin
affinity followed by PNGase F digestion coupled to 18O labeling, we
identified 34 glycosylation sites. This study indicates that quantitative
proteomic profiling of tumor tissue versus non-cancerous tissue is a
promising approach for the identification of potential biomarkers for
HCC.
027: Embryonic stem cells, their biomedical potential
and proteomics approach for quality control
1K. S. Rakesh, 2Dawood Dudekula, 2Nagaraja Ramaiah,
2S. H. Ko Minoru, 1Ravi Sirdeshmukh
1Centre for Cellular and Molecular Biology, Hyderabad 500 007,
India, 2Laboratory of Genetics, National Institute on Aging, 251,
Bayview Blvd., Suite 100, Baltimore, MD, 21224, USA
Stem cells have great potential for developing new approaches for the
treatment of degenerative diseases including neurons, skeletal and
cardiac muscles, beta cells of pancreas, and cancer cells. Cell
replacement therapy with stem cell and their derivatives are thus an
important biomedical tool. A better understanding of the molecular
pathways, regulatory networks and their dynamics, which determine
their diverse differentiation fates, is needed for these therapeutic
approaches to be successful. With these objectives, we have been
studying protein expression in mouse embryonic stem cell lines (R1-9
and ABI), as model system. We have extensively studied their protein
profiles by ESI LC MS/MS approach, integrated the data with
transcriptomics studies as well as with proteomics studies from other
laboratories. We have thus identified more than 2,000 proteins
expressed in stem cells with high confidence. Pathway analysis of
these proteins was carried out using KEGG, IPA, GenMAPP and their
gene ontology classification revealed transcription regulators, signal
transducers, cell cycle and differentiation molecules along with other
general classes of proteins. Based on the specific proteins expressed,
putative regulatory pathways operational in stem cells could be
constructed. Such information on protein expression and plausible
biochemical pathways and networks operational in the stem cells and
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their derivatives would be useful in defining cell states and devel-
oping quality control methods for their biomedical application.
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Type 2 Diabetes Mellitus (T2DM) is a polygenic disorder with both
gene–environment and protein–protein interactions influencing the
disease risk. A huge effort to unravel the risk factors has been
undertaken worldwide for over a decade but with little success. On
these lines, we designed a system biology approach to identify
plausible disease candidates by assigning a score called weight value
(Wv) ranging from 0 to 1 based on domain interactions and sub-
sequent network analysis. Using this approach we identified certain
already known T2DM proteins and also captured proteins of unknown
functions and several new candidates for this dreaded disease. Our
analysis revealed Lipin family member: Lipin-2 and Lipin-3 to be
probable disease candidates in T2DM. Hence, to validate our
approach, the functional characterization and identification of Lipin
family was done in zebrafish model system. There are three members
of lipin family having Phosphatidic acid phosphate (PAP) enzyme
activity, responsible for generating diacylglycerol utilized in the
synthesis of triacylglycerol (TAG). The regulation of TAG storage is
important in human disease because both excessive and inadequate
food storage might lead to abnormalities like insulin resistance and
diabetes. Protein sequence alignment and phylogentic analysis of
three unknown proteins in zebrafish showed high similarity to that of
three human lipin family members. Expression analysis using Reverse
transcriptase PCR of total RNA obtained from different tissues of
zebrafish revealed the expression of Lipin-1, 2 and 3 proteins in
intestine, gills, muscle, ovary, liver and kidney. In situ hybridization
of Lipin members (Lipin-1, 2 and 3) revealed that all the three had
expression pattern centered in eye and head region of 24 h post fer-
tilization (hpf), 36hpf, 48hpf and 72hpf embryos. Thus, further studies
assessing the roles of these three proteins in zebrafish would assist in
defining their explicit role in human diseases.
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Breast cancer is one of the most common malignancies among women
worldwide. Despite tremendous advances in screening, diagnosis, and
treatment, the causes of this disease remain elusive and complex.
Protein-based breast cancer biomarkers are a primary resource for
breast cancer detection at the earliest and most treatable stages of the
disease. Blood is an easily accessible source of proteins, which have
diagnostic value, as it is in contact with practically all tissues in the
human body. The vast dynamic range of protein abundance in blood
plasma represent a major challenge in applying a proteomic based
strategy for their identification. From an experimental design point of
view, most cancer biomarker studies, including those aimed at identi-
fying markers for early detection, are initiated with analysis of
specimens from newly diagnosed subjects. The discovered candidate
biomarkers are subsequently investigated for their utility for early
cancer diagnosis. Differential protein expression in the breast cancer
and healthy individual’s plasma samples was investigated by two
dimensional gel electrophoresis (2-DE), and spots showing a signifi-
cantly expression between the two were analyzed. Image matching
derived from two sets showed total of 112 spots. Out of 112, 2 proteins
were up-regulated or present in patient’s plasma samples as compared
to control and 3 protein spots were found to be differentially expressed
by means of quantitative analysis. This investigation can lead to the
development of potential biomarker that may have clinical utility in
discovering biomarkers of breast cancer.
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Aims: Epithelial ovarian cancer (EOC) presents in the later stages of
the disease. Regulatory genes/transcription factors (TFs) control the
functions of various genes associated with cancer development. We
hypothesized that over expressed TFs associated with EOC patho-
genesis could be useful tissue and serum markers for malignancy
associated with EOC.
Methods: Using microarray data we shortlisted candidate genes
associated with apoptosis and cell structure integrity. Using promoter
and TF binding analysis we shortlisted target TFs that could play a
key role in malignancy associated with EOC. Using immunoblotting
and IHC we validated the in silico predictions and associated these
markers with CA125 for their clinical utility.
Results: Using a combined genomic-bioinformatics and proteomic
approach we identified potential regulatory genes associated with the
pathogenenicity of EOC. EOC-specific microarray data were examined
for over-expressed genes. Promoter models of over-expressed genes
were determined and bioinformatic analysis implicated transcription
factors ZEB1, E2F5, PAX8 and ELF3, involved in cell proliferation, as
promising regulatory targets in early stage disease. Additional analysis
found E2F5 as a prime candidate for further study. Our in silico
observation was supported by tissue microarray experiments that
showed E2F5 expression only in EOC samples and not in normal and
benign tissues as observed in a total of 135 (111 tumours and 24 nor-
mal) tissue array (45.6% of EOC tissue samples) and 144 serum
(Normal: 56, benign: 40 and malignant: 48) 81.25%, p = 0.0001
patients with EOC). Analysis of clinical characteristics of this protein
used in different combinations with CA125 for distinguishing malig-
nant cyst from benign cyst shows increased sensitivity (97.9%; increase
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from 87.5% if CA125 only is used) and more importantly increased
specificity (72.5%; increase from 55% if CA125 only is used). This
significantly improved accuracy suggests improved diagnostics of
EOC. Overall, our findings provide evidence that some of the cell-cycle
regulatory proteins might play a significant role in EOC pathogenesis.
Conclusion: Our findings show involvement of E2F genes in EOC
development and progression. Larger prospective studies are essential
to validate our findings. We have demonstrated the application of
microarray analysis could facilitate the identification of genes, genetic
pathways, and proteins involved in the pathogenesis of EOC and their
utility as potential serum markers.
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The Biobase Knowledge LibraryTM Disease View presents detailed
information on 1988 different human diseases with the aim of helping
researchers to understand the molecular mechanisms underlying
human disease. More than 5,234 proteins are associated with disease
terms resulting about 30,000 protein-disease links. Disease View
provides manually curated links between genes and MeSH terms in
four major categories: biomarker, therapeutic target, molecular
mechanism and negative correlation; as well as information on
expression of gene or protein in a particular disease condition and
knockout models. Each disease report provides detailed information
about the effects of molecular alterations on the biological processes
associated with the respective gene. Information is provided for 4,284
biomarkers, 1,311 therapeutic targets, and 94,461 annotations com-
prising 4,937 polymorphisms, 12,749 mutations, etc.
Disease View is closely integrated with TRANSFAC, a database
on gene regulation and transcription factors, and TRANSPATH, a
database on signal transduction and metabolic pathways. Integrated
databasing allows the user to make sophisticated queries and to gen-
erate new information based upon multiple facts brought together from
the dispersed literature. As an example workflow through the integrated
BKLTM, one could identify all proteins associated with metabolic
disorders, as well as those involved in signaling and metabolic path-
ways and gene regulatory networks. With the help of the accompanying
tools, one could (1) retrieve the promoters of the corresponding genes,
(2) identify putative TF binding sites and (3) analyze networks to find
potential key nodes.
An exclusive feature of the BKLTM is the interlinking with
the internationally acclaimed Human Gene Mutation Database
(HGMD) curated at Cardiff University. The HGMD represents a
comprehensive core collection of germ-line mutations in nuclear
genes underlying or associated with human inherited disease. The
database contains over 79,000 different lesions detected in 3,000
different human genes, with new entries currently accumulating at a
rate exceeding 9,000 per annum. HGMD records the first report of a
disease-causing mutation or disease-associated/functional polymor-
phism. The data comprise single base-pair substitutions in coding,
regulatory and splicing-relevant regions of human nuclear genes,
micro-deletions and micro-insertions, indels, repeat expansions, gross
lesions and complex rearrangements.
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Retinoblastoma (RB) is the most common intraocular malignancy of
infancy and childhood in which epithelial cell adhesive molecules
(EpCAM) was found to be over expressed and associated with
invasion of the choroids and optic nerve. But surprisingly Y79 RB
cell line did not show any EpCAM expression. However the molec-
ular mechanisms responsible for the downregulation of EpCAM in
Y79 RB cell line was not known. DNA methylation is an important
mechanism for inactivating various genes during tumourigenesis and
progression. The presence of a CpG island in the TACSTD1 gene
promoter and first exon, encoding EpCAM, led us to investigate in
this study whether EpCAM expression can be influenced by DNA
methylation. We examined the methylation status of the TACSTD1
promoter region RB cell lines using bisulfite sequencing. We found
the promoter of EpCAM-negative Y79 RB cell line to be methylated
to a higher degree. Demethylation of cell lines was performed using
5azacytidine (AZC). TaqMan gene expression assays were used to
quantify the mRNA expression of EpCAM normalized against two
endogenous controls using geNorm software. Immunofluorescence
(IF) was carried out using EpCAM antibody. EpCAM RNA and
protein expression could be partially restored by treating cells with
AZC. By real-time PCR the EpCAM RNA expression increased more
than 250-fold after 5 days of incubation with AZC compared to the
untreated cell line, and by IF it was resulted in the expression of
detectable amounts of EpCAM protein on the cell surface. We have
also attempted to determine the changes in the other protein profile
changes in AZC treated Y79 cell line. The strategy applied makes use
of proteomics technologies to reveal and identify other proteins that
are differentially regulated in control and in AZC treated cells. We
have identified and analyzed 16 differentially expressed proteins in
Y79 using 2DE-MS approach. The identity of most of these differ-
entially expressed proteins was determined by 4,800 MALDI TOF
TOF. We found 13 proteins are up regulated and 3 proteins were
downregulated in AZC treated cells compared to untreated Y79. The
functional significance of all the proteins was identified from swiss-
prot. Taken together, these data suggest that epigenetic inactivation of
genes by DNA methylation can be reversed by treatment with the
DNA methylation inhibitor AZC. Our study will provide a basis for
further investigation into metabolic pathways affected by demethy-
lating drugs and their mode of action.
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